CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orgenesis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orgenesis Inc
20271 Goldenrod Lane
Phone: (480) 659-6404p:480 659-6404 GERMANTOWN, MD  20876  United States Ticker: ORGSORGS
Business Summary
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
7389 Business services, not elsewhere classified
5047 Medical, dental, and hospital equipment and supplies
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairperson of the Board of Directors, Chief Executive Officer VeredCaplan 55 1/22/2019 2/2/2012
Chief Financial Officer, Treasurer, Secretary VictorMiller 55 1/2/2024 1/2/2024
Independent Director YaronAdler 53 4/17/2012 4/17/2012
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Tamir Biotechnology Inc 12625 High Bluff Dr. San Diego CA United States
Tissue Genesis, Inc. 810 Richards Street Ste 1000 Honolulu, Hawai HI United States
Orgenesis Maryland LLC 1812 Ashland Avenue Baltimore MD United States
Koligo Therapeutics Ltd 126 Phillip Street, Level 5, Sydney Sydney NSW Australia

Business Names
Business Name
Atvio Biotech Ltd.
BOUT
Cell Therapy Holdings S.A.
12 additional Business Names available in full report.

General Information
Number of Employees: 146 (As of 12/31/2023)
Outstanding Shares: 5,169,248 (As of 11/13/2024)
Shareholders: 346
Stock Exchange: OTC
Federal Tax Id: 980583166


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024